New LaunchMay 27, 2026, 10:38 AM
Conexeu Sciences Launches Preclinical Program for B.R.E.A.S.T.™ Matrix
AI Summary
Conexeu Sciences Inc. announced the launch of a preclinical development program for its B.R.E.A.S.T.™ (BIO-REGENERATIVE ERGONOMICALLY ARCHITECTED SMART TISSUE™) 3D-printed bioregenerative breast matrix. The program, conducted at the Wake Forest Institute for Regenerative Medicine (WFIRM), will evaluate the durability, host tissue integration, and resorbability of the proprietary CXU™ 3D-printed matrix. This initiative is a significant step in advancing the company's regenerative medicine strategy and aims to develop an alternative to traditional breast implants and reconstruction approaches. Conexeu anticipates a 510(k) submission for its initial indication in early 2027.
Key Highlights
- Launched preclinical development program for B.R.E.A.S.T.™ 3D-printed bioregenerative breast matrix.
- Program conducted at the Wake Forest Institute for Regenerative Medicine (WFIRM).
- Evaluates durability, host tissue integration, and resorbability of the proprietary CXU™ matrix.
- B.R.E.A.S.T.™ is designed as a resorbable, bioregenerative matrix for soft tissue restoration.
- Leveraging support from the RegenMed Development Organization (ReMDO) ecosystem.
- Aims to provide an alternative to permanent breast implants and traditional reconstruction.
- Anticipates a 510(k) submission for its initial indication in early 2027.
Price Impact
More from CNXU